News Focus
News Focus
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Protector post# 274358

Tuesday, 10/04/2016 6:22:01 AM

Tuesday, October 04, 2016 6:22:01 AM

Post# of 347009
I truly like the way this is playing out. I will admit even I thought (when I first heard 5000 samples) that it may have meant one needed 5,000 patients and I am glad I was wrong to think that!

About 500 patients and about 10 blood test samples each gives us the 5,000 as you said CP ...and more importantly....A BEAUTIFUL representation of key, multiple levels of proteins that make up MDSCs are the real puzzle pieces that can now allow an MD to have scientific proof a treatment is working: A PS Targeting treatment is working!

I found this one article that mentions 63 key proteins within MDSCs (that change 2x in inflammation) and since Peregrine has already publicly disclosed that PS Targeting reduces MDSCs by a statistically significant 40%...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=122686560&txt2find=Reduce%7CMDSCs%7C40%25

now we wait till Oct 10 to hear more about possibly some of the key proteins...

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125520266&txt2find=63%7Cproteins

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y